title: Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization.
abstract: OBJECTIVE
  To investigate associations between outcome of anti-vascular endothelial growth factor (VEGF) therapy and choroidal morphology in eyes with myopic choroidal neovascularization (CNV).
  
  
  METHODS
  Fifty-two eyes of 46 patients with myopic CNV received a single intravitreal anti-VEGF injection, followed by as-needed injections. Baseline choroidal thickness was measured at the fovea and 1.5 and 3 mm nasal, temporal, superior, and inferior to the fovea using enhanced depth imaging optical coherence tomography. Measurements were compared between eyes with and without CNV resolution after a single injection and between those with and without CNV recurrence within 1 year of initial injection. Associations between treatment outcomes and morphologic or clinical factors were assessed using regression analyses.
  
  
  RESULTS
  Patients received 1.8 ± 1.3 intravitreal injections during follow-up. Eyes with CNV resolution after a single anti-VEGF injection had a significantly thicker inferior choroid than those without resolution (67.3 ± 32.9 vs. 44.5 ± 17.6 μm, P = 0.002). The subfoveal choroid was thinner in eyes with recurring CNV than in those without recurrence (35.7 ± 23.7 vs. 52.0 ± 20.8 μm, P = 0.029). Associations were found between inferior choroidal thickness and CNV resolution (P = 0.019) and between subfoveal choroidal thickness and 1-year recurrence rates (P = 0.016). Adjusted odds ratios were 9.1 for CNV resolution with an inferior choroidal thickness >49 μm and 5.6 for recurrence within 1 year with a subfoveal choroidal thickness ≤47.5 μm.
  
  
  CONCLUSIONS
  A thinner subfoveal/inferior choroid at baseline may indicate poor anatomic outcome after intravitreal anti-VEGF treatment in eyes with myopic CNV.
authors: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
authors: Seong Joon
authors: SJ
authors: Ahn
authors: Se Joon
authors: SJ
authors: Woo
authors: Ko Eun
authors: KE
authors: Kim
authors: Kyu Hyung
authors: KH
authors: Park
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D002829:Choroid / Q000473:pathology*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005584:Fovea Centralis / Q000187:drug effects; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000188:drug therapy* / Q000473:pathology; D000069579:Ranibizumab; D012044:Regression Analysis; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab